Formulation and in vitro/in vivo evaluation of zidovudine contained in solidified reverse micellar delivery system of immune compromised rats

Journal of Applied Pharmaceutical Science

Volumn 3, Issue 2, 2013, Pages 31-35

  Uronnachi Emmanuel, M ^a   Ogbonna John, D N ^a   Kenechukwu Franklin, C ^a   Attama Anthony, A ^a   Okore Vincent, C ^a  

^a UNIVERSITY OF NIGERIA   (Nigeria)

Author keywords

Immune compromised; Invitro in vivo correlation; Lipid matrix; Phospholipon 90H; Solidified reverse micellar microparticle (SRMM)

Indexed keywords

EID: 84876056428     PISSN: None     EISSN: 22313354     Source Type: Journal    
DOI: 10.7324/JAPS.2013.30206     Document Type: Article

References (19)

1. Attama AA, Nkemnele MN. In vitro evaluation of drug release from self-emulsifying drug delivery systems using a biodegradable homolipid from Capra hircus. Int. J. Pharm 2005;304:4-10.
2. Bird GA. Non-HIV AIDS: nature and strategies for its management. J Antimicrobial Chemo 1996; 37(Supp. B):171-183.
3. European Community Council Directive on the ethics of experiments involving laboratory animals (86/609/EEC), Nov. 24, 1986.
4. Erni C, Suard C, Freitas S, Dreher D, Merkle HP, Elke W. Evaluation of cationic solid lipid microparticles as synthetic carriers for the targeted delivery of macromolecules to phagocytic antigen-presenting cells. Biomaterials 2002;23:4667-4676.
5. Guidance for industry, extended release oral dosage forms: development, evaluation and application of an in vitro/in vivo correlation. FDA, CDER, 1997.
6. Hu FQ, Yuan H, Zhang HH, Fang M. Preparation of solid lipid nanoparticles with clobetasol propionate by a novel solvent diffusion method in aqueous system and physicochemical characterization. Int. J. Pharm 2002;239:121-128.
7. th International Symposium on Microencapsulation, Parma, (Italy), 2005.
8. Kuksal A, Tiwary AK, Jain NK, Jain S. Formulation and In Vitro, In Vivo Evaluation of Extended- release Matrix Tablet of Zidovudine: Influence of Combination of Hydrophilic and Hydrophobic Matrix Formers. AAPS PharmSciTech 2006; 7(1): Article 1.
9. Kumar, A., Lahiri, S.S., Singh, H., Development of PEGDMA: MAA based hydrogel microparticles for oral insulin delivery. Int. J. Pharm 2006; 323(1-2):117-124.
10. rd ed. Marcel Dekker Inc; 2002. p. 2701- 2712.
11. Lippacher A, Muller RH, Mader K. Preparation of semisolid drug carriers for topical application based on solid lipid nanoparticles. Int J Pharm 2001;214:9-12.
12. Müller-Goymann CC, Friedrich I. Characterization of solidified reverse micellar solutions and production development of SRMS-based nanosuspensions. Eur. J. Pharm. Biopharm, 2003;56(1):111-119.
13. Morel S, Ugazio E, Cavalli R, Gasco MR. Thymopentin in solid lipid nanoparticles. Int. J. Pharm 1996;132:259-261.
14. Reithmeier H, Herrmann J, Gopferich A. Lipid microparticles as a parenteral controlled release device for peptides. J Control Release 2001;73:339-350.
15. Salsa T, Veiga F, Pina ME. Oral controlled-release dosage forms. I. Cellulose ether polymers in hydrophilic matrices. Drug Dev Ind Pharm 1997;23:929-938.
16. Schwarz C, Mehnert W, Lucks JS, Muller RH. Solid lipid nanoparticles (SLN) for controlled drug delivery. I. Production, characterization and sterilization. J Control Release 1994;30:83-96.
17. Trotta, M., Cavalli, R., Carlotti, M., E., Battaglia, L., Debermardi, F. Solid lipid microparticles carrying insulin formed by solvent-in-water emulsion diffusion technique. Int. J. Pharm 2005;228(2):281-288
18. Uronnachi EM, Ogbonna JDN, Kenechukwu FC, Attama AA, Chime SA Properties of zidovudine loaded solidified reverse micellar microparticles prepared by melt dispersion. Journal of Pharmacy Research 2012;5(5):2870-2874
19. United States Pharmacopoeia. In vitro and In vivo Evaluations of Dosage Forms, 27th edition, Revision, Mack Publishing Co., Easton, PA; 2004.